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Abstract
Background: Neurogenic thoracic outlet syndrome (nTOS) is a disease process caused by the compression
of neurovascular structures passing through the anatomical thoracic outlet. This compression can manifest as
pain, paresthesia, progressive muscle weakness and subsequent muscle loss of the effected limb. Current
mainstay treatment for patients with nTOS is conservative therapy and surgical decompression. However, in
recent years, botulinum toxin, which is a neuromuscular junction blocking agent has been effective as a short-
term treatment.
Method: A literature search using the following search engines CINAHL, MEDLINE-OVID, EBMR
Multifile and Web of Science was conducted using the following search terms: thoracic outlet syndrome,
botulinum toxin and Botox. Inclusion criteria were: adults diagnosed with thoracic outlet syndrome who were
being treated with botulinum toxin injections alone, studies in English, dates from 2000-2012. Studies
excluded if patients had previous surgical intervention for TOS and evaluated using the GRADE system.
Results: Three studies met inclusion criteria. A double-blind, randomized, controlled trial involving 38
patients used ultrasound-guided Botox injections in the scalene and pectoralis minor muscles for treatment of
patients with nTOS. Results showed no clinical difference in treatment and placebo groups when compared
on a visual analog scale. A prospective longitudinal study involving 27 patients receiving CT-guided low dose
Botox injections to the anterior scalene muscle, resulted in as much as 47% reduction in pain. Lastly, a
prospective study that enrolled 22 subjects examined nTOS patients response to electrophysiologically and
fluoroscopically guided Botox injections in the anterior scalene, middle scalene and pectoralis minor muscles,
demonstrated a greater than 50% reduction of pain in 64% of the cohort.
Conclusion: Two quasi-experimental studies demonstrated Botox injections in the scalene muscles and
pectoralis minor muscle to be effective in symptomatic treatment of nTOS but results of a recent randomized
controlled trial show no clinical significance. All relevant articles revealed limitations, with each of the studies
needing a larger sample size, better randomization, blinding techniques and a more specific and well defined
inclusion criteria.
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Abstract   
 
Background:  Neurogenic thoracic outlet syndrome (nTOS) is a disease process caused by the 
compression of neurovascular structures passing through the anatomical thoracic outlet. This 
compression can manifest as pain, paresthesia, progressive muscle weakness and subsequent 
muscle loss of the effected limb.  Current mainstay treatment for patients with nTOS is 
conservative therapy and surgical decompression.  However, in recent years, botulinum toxin, 
which is a neuromuscular junction blocking agent has been effective as a short-term treatment.  
Method:  A literature search using the following search engines CINAHL, MEDLINE-OVID, 
EBMR Multifile and Web of Science was conducted using the following search terms: thoracic 
outlet syndrome, botulinum toxin and Botox.  Inclusion criteria were: adults diagnosed with 
thoracic outlet syndrome who were being treated with botulinum toxin injections alone, studies in 
English, dates from 2000-2012. Studies excluded if patients had previous surgical intervention for 
TOS and evaluated using the GRADE system.  
 
Results: Three studies met inclusion criteria.  A double-blind, randomized, controlled trial 
involving 38 patients used ultrasound-guided Botox injections in the scalene and pectoralis minor 
muscles for treatment of patients with nTOS.  Results showed no clinical difference in treatment 
and placebo groups when compared on a visual analog scale.  A prospective longitudinal study 
involving 27 patients receiving CT-guided low dose Botox injections to the anterior scalene 
muscle, resulted in as much as 47% reduction in pain. Lastly, a prospective study that enrolled 22 
subjects examined nTOS patients response to electrophysiologically and fluoroscopically guided 
Botox injections in the anterior scalene, middle scalene and pectoralis minor muscles, 
demonstrated a greater than 50% reduction of pain in 64% of the cohort.   
Conclusion: Two quasi-experimental studies demonstrated Botox injections in the scalene 
muscles and pectoralis minor muscle to be effective in symptomatic treatment of nTOS but 
results of a recent randomized controlled trial show no clinical significance.  All relevant articles 
revealed limitations, with each of the studies needing a larger sample size, better randomization, 
blinding techniques and a more specific and well defined inclusion criteria. 
Keywords:  Botulinum toxin, Botox, Thoracic Outlet Syndrome, Botulinum toxin type A, 
Neurogenic Thoracic Outlet Syndrome, 
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Efficacy of Scalene Muscle Botulinum Toxin Injection for the Treatment of 
Neurogenic Thoracic Outlet Syndrome 
BACKGROUND 
 Thoracic outlet syndrome (TOS) is considered to be a spectrum of symptoms 
caused by compression of neurovascular structures that pass through the thoracic outlet.1 
The term "Thoracic Outlet Syndrome" was first given by Peet et al2 in 1956, to describe a 
condition caused by the compression of neurovascular structures in the upper 
extremity.3,4 The Thoracic Outlet is an anatomical space defined by the superior edge of 
the first rib, posterior border of the clavicle, lateral border of the mediastinum and the 
bony landmarks of the spinal column to the fifth cervical rib.5  Within the Thoracic 
Outlet, the scalene triangle is most commonly involved in the compression of the brachial 
plexus.6  There are three main subtypes of TOS that are categorized by the principally 
affected structure involved in symptoms3.  The three subtypes are neurogenic (nTOS) due 
to brachial plexus compression, arterial (aTOS) due to subclavian artery compression, 
and venous (vTOS) due to subclavian vein compression.7 Neurogenic TOS is the most 
common subtype, making up 95% of cases.7 The brachial plexus, subclavian artery and 
vein are particularly susceptible to injury and compression when passing through either 
the costoclavicular space, scalene triangle or pectoralis minor space.8 The "space 
problem" as proposed by Brantigan and Roos5 can arise from congenital or post-
traumatic bony and soft tissue anomalies such as a cervical rib, first rib deformities, 
displaced fractures, scalene muscle fibrosis, scalene muscle hypertrophy and scalene 
muscle insertion anomalies.  The anterior scalene muscle (ASM) and middle scalene 
muscles (MSM) originate from the transverse processes of cervical vertebrae 2-7 and 
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insert on the first rib. Both the ASM and MSM, function as an accessory muscle to 
respiration by elevating the first rib.9 The brachial plexus along with the subclavian artery 
and vein traverse through the scalene triangle that is created by the origin and insertion of 
the ASM and MSM.   
 Standard imaging techniques and testing is generally not effective at assisting in 
the diagnosis of TOS.  This burden is then passed on to patients who are left with an 
incapacitate disease that is largely unrecognizable by most clinicians.  Along with the 
difficulty of diagnosing TOS, it is just as difficult to know where to start treatment.3 To 
date, one of the most reliable methods to diagnose nTOS is by a neuromuscular blocking 
agent injection to the anterior scalene muscle at its insertion on the first rib.3 As reported 
through multiple studies4,10,11, lidocaine or bupivicaine injected in the ASM under 
computed tomography (CT) guidance or ultrasound guidance has been shown to 
successfully alleviate symptoms caused by compression of the neurovascular structures in 
the scalene triangle.  The lidocaine and bupivacaine injections however, are only 
effective for a few hours.  Furthermore, these studies4,10-12 demonstrated that imaging 
guided botulinum toxin injections in the ASM provided the same relief as lidocaine and 
bupivacaine, but Botox lasted for a duration of approximately 3 months.  With limited 
options for management of nTOS, patients who have not benefited from conservative 
treatment, such as physical therapy, exercise and massage therapy, have often found 
botulinum toxin injections to be a useful approach for those not able to tolerate surgical 
intervention or as a bridge to surgical treatment4,10,11.  The question remains, how 
effective is the use of botulinum toxin injected into the scalene muscles for short-term 
and/or long-term symptomatic relief of neurogenic thoracic outlet syndrome.  
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METHODS 
 A literature search using the following search engines CINAHL, Medline-OVID, 
EBMR Multifile and Web of Science was conducted using the following search terms: 
thoracic outlet syndrome, botulinum toxin and Botox.  Inclusion criteria were: adults 
diagnosed with thoracic outlet syndrome who were being treated with botulinum toxin 
injections alone, studies in English, dates from 2000-2012. Studies were excluded if 
patients had previous surgical intervention for TOS.  The quality of evidence for all 
relevant articles was then evaluated using the grades of recommendation, assessment, 
development and evaluation (GRADE) system.13   
RESULTS 
 The search using keywords, Thoracic Outlet Syndrome, Botulinum Toxin, Botox 
and a timeline of 2000-2012, yielded a total of 24 articles.  After reviewing all eligible 
articles, only 3 met the inclusion criteria. The articles included were a double-blind, 
randomized, controlled trial by Finlayson et al12, a prospective longitudinal study by 
Christo et al4 and a prospective study by Jordan et al11.    
Finlayson et al study 
 This double-blind, randomized, controlled trial12 was performed in Canada and is 
the first of its kind to evaluate the efficacy of EMG-guided botulinum toxin injections for 
the treatment of TOS. Thirty-eight patients were selected and randomized to receive an 
injection to the scalene muscles of either 75cc of botulinum toxin type A (BTX-A) 
reconstituted with 0.75cc of normal saline or 0.75cc of normal saline alone to the scalene 
muscles. Patients were followed for a total of 6 months. The primary outcome of the 
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study was pain using a 100-mm horizontal visual analog scale (VAS) with scores in a 
range of 0-100.  Secondary scores were paresthesias measured by VAS, Disability of the 
Arm, Shoulder, and Hand (DASH) questionnaire, SF-36 Health Survey physical and 
mental scores.  Pain scores were noted at baseline, 6 weeks, 3 months, and 6 months post 
injection, with the primary outcome of interest being evaluated at 6 weeks.12   
 Criteria for eligibility in the study included patients with a clinical diagnosis of 
TOS presenting with symptoms for a minimum of 6 months, 19 years of age or older, 
medically stable, mentally and physically sound to give informed consent, prior 
electromyography (EMG) and a magnetic resonance imaging (MRI) or a computed 
tomography (CT) of the cervical spine for ruling out bony abnormalities or anomalies.  
Patients were excluded from the study if they had prior BTX-A therapy; BTX-A allergy; 
history of botulism; scalenectomy; TOS surgery scheduled in the upcoming 6 months; 
current anticoagulant therapy; diagnosis of myasthenia gravis or Eaton-Lambert 
syndrome; were pregnant; unable to complete follow up at 6 weeks, 3 months, and 6 
months post injection.  Subjects were randomized to each group using a computer 
random number generator carried out by a statistician who was not a co-investigator.  As 
soon as a subject was enrolled into a group, a first study investigator confirmed treatment 
for that individual, prepared the solution and presented it to a second investigator who 
would perform the injection. The treatment plan was concealed in a locked filing cabinet 
and only known to the first investigator. Contents in both the BTX-A and placebo syringe 
were identical in appearance and quantity to ensure the injector and subject could not 
identify which group they were associated with.12    
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 According to the VAS, botulinum toxin type A treatment did not have significant 
changes in average pain scores from baseline when compared to placebo according to the 
VAS.  The difference in pain scores between the two groups was measured at 5.03 mm in 
favor of the treatment group (95% CI -15.7 to 5.69, P = 0.36).  At 6 weeks follow up, 6 of 
the 20 patients in the BTX-A group (30%) and 2 of the 18 patients in the placebo group 
(11%) reported a 30% or greater reduction in pain when compared to baseline (difference 
= 19%, 95% CI: -8% to 42%, P = 0.24).  Secondary outcomes were not averaged and 
varied from subject to subject.12 
 Finlayson et al12 reported no clinical or statistical significance between the BTX-
A and the placebo groups.  They did however, point out several limitations to the study.  
The average duration of symptoms in the BTX-A group before being enrolled in the 
study was found to be 6 years; in comparison those in the placebo group had been 
symptomatic for an average of 3 years despite efforts at randomization. They also did not 
identify or assess patients for chronic pain syndrome, which may not be successfully 
treated with a single intervention.  Although needle placement was confirmed using EMG 
guidance, other studies4,11 that have reported significant reduction in pain post BTX-A 
injection used CT-guidance4 and flouroscopic guidance.11  This may suggest that EMG 
guidance is not as accurate as other imaging techniques. The authors12 also felt that their 
methods of blinding "were suboptimal".  Findlayson et al concluded that the lack of pain 
reduction in BTX-A subjects could be attributed to patients with long standing symptoms 
who potentially have chronic pain syndrome.  They suggest future studies should involve 
patients with a shorter duration of TOS symptoms.12  
Christo el al study 
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  This prospective longitudinal study4 looked at the efficacy of low dose, CT-
guided, single botulinum toxin injection of the anterior scalene muscle for symptomatic 
relief of neurogenic thoracic outlet syndrome.  Twenty-seven patients were followed over 
a period of 3 months.  The primary outcome was pain relief as measured by the Short-
form McGill Pain Questionnaire (SF-MPQ).  Selected patients with a diagnosis of TOS 
received 1cc of 0.25% bupivicaine to the anterior scalene under CT-guidance.  Those 
who had a greater than 50% reduction in pain and improved ability to perform an 
elevated arm stress test (EAST) were considered for botulinum toxin injection.  From 
there, each eligible subject was given 20 units of Botox in the anterior scalene.  Pain 
scores were recorded at 4 intervals; baseline, 1 month, 2 months, and 3 months post 
injection.4   
 Eligibility criteria for subjects were age 18 or older, no prior TOS surgical 
intervention, radiographic confirmation of normal cervical spine anatomy and positive 
elevated arm stress test (EAST).  The procedure was carried out with patients in the 
supine position and a 25-guage needle was placed into the ASM that was confirmed with 
radiographic contrast.  Once needle placement was confirmed, 20 units of Botox was 
injected without any repositioning of the needle.  In order to confirm proper placement 
and spread of Botox in the ASM, a focal-scan was performed.4  
 Results of SF-MPQ convey a marked reduction in pain during the three months 
post injection as indicated by the four components; sensory (P = 0.02), total (P = 0.05), 
VAS (P = 0.04), and present pain intensity (PPI) score (P = 0.06).  Median score of pain 
as suggested by the above four components decreased by 30-42% during the first month, 
29-47% during the second month, and 14-33% during the third month.  According to the 
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present pain intensity (PPI) score, more intense pain is given a score of 3, 4, or 5.  Pre-
Botox, approximately 75% of participants reported their pain as "more intense".  After 
treatment, less than 50% of subjects reported "more intense" pain during the three month 
follow up.  Side effects reported by subjects were few, with neck weakness being the 
most prevalent.4 
 Christo et al4 reported significant decreases in pain as measured by SF-MPQ.  The 
researchers3 also stated that they used a lesser amount of Botox at 20 cc in comparison to 
at least 100 cc used in similar trials10-12 and this yielded comparable results.  They 
concluded that due to complication of surgical intervention and large-scale resultant 
disability (30% and 60% respectively), it is vital that alternative treatments such as the 
one examined here be pursued and perfected.14  
Jordan et al study 
 In this prospective study,11 researchers examined the effects of botulinum toxin as 
a bridge therapy for patients diagnosed with TOS who were being evaluated for surgery.  
Twenty-two patients were selected and followed for 6 months.  Each patient was to 
receive a total of 100 units of botulinum toxin dissolved in 1mL of saline, delivered to the 
anterior scalene muscle, middle scalene muscle and trapezius muscle.  All injections were 
to be electrophysiologically and fluoroscopically guided to ensure precision at each 
injection site.  Primary outcomes were pain and symptomatic relief as measured by a 
101-point analog scale.11 
 In order for participants to meet eligibility criteria they needed to have a clinical 
diagnosis of nTOS and a minimum of 2 years with stable clinical symptoms.  A cervical 
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MRI for all subjects was obtained to rule out bony abnormalities or anomalies.  Each 
patient had already attempted and failed at more conservative therapy.  During the 6 
month trial, patients were still being treated with physical therapy, medications and 
workplace ergonomic adjustments.11   
 Accurate placement of the needle was confirmed with iodinated contrast injected 
into the anterior scalene muscle.  A 2mL mixture of 2% lidocaine and 1.5 mg of 
betamethasone sodium phosphate was injected into the anterior scalene as an anesthetic 
blockade.  Patients were then reexamined to identify their degree of pain.  If a subject 
reported  > 50% pain relief on the 101-point analog scale, they were considered for Botox 
injections.  Botox injections were then carried out in the same fashion with 12 units 
injected into the ASM, 12 units injected into the MSM, and the remaining 76 units 
injected into the ipsilateral trapezius muscle.11 
 Follow up results demonstrated a significant decrease in pain scores with 64% of 
patients reporting  > 50% pain relief for longer than 1 month.  As reported by Jordan et 
al11 "the mean duration of improvement after botulinum injection was 88 days with a 
range of 30 - 180 days".  Similar to other researchers,4,10 Jordan et al11 found botulinum 
toxin to be a valuable treatment for patients awaiting surgery but not a long-term 
definitive treatment.11                           
DISCUSSION 
 Surgery is the current mainstay treatment for patients that have failed 
conservative management.  For patients who are not surgical candidates, Botox injection 
may provide an alternative treatment option to more invasive procedures such as 
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scalenectomy or rib resection.  Furthermore, long-term success rates for surgical 
interventions, range from 40-65% but have been shown to diminish over time.14,15  In two 
of the studies, 4,11 botulinum toxin used as therapy for nTOS has been shown to be a safe, 
effective, short-term, non-surgical approach to treatment for patients who have failed 
conservative therapy or not considered to be a good candidate for surgery.  However, the 
one RCT reviewed,12 failed to demonstrate efficacy.  There are several limitations in all 
of these studies which makes it difficult to truly know the effects of scalene muscle 
Botox injections and whether or not they should be considered by clinicians with patients 
looking to defer or avoid surgery.  
 Aside from BTX-A as a treatment for TOS, it has also been suggested that 
botulinum toxin can be an effective bridge therapy for patients who are waiting for 
elective surgery.11  This idea of a bridge therapy could benefit from a study that looks at 
patients preparing for non-expeditious surgery to correlate success of BTX-A treatment 
results with surgical results.  For all of these aforementioned reasons further research is 
warranted on this non-surgical approach to treatment.   
 One of the largest flaws of the Finlayson et al study12 that the authors did not 
address is the small population size, which may be a reason as to why they interpret there 
to be no significant difference between the treatment and placebo groups.  While a 19% 
difference in pain reduction between BTX-A and placebo may not seem significant in a 
population of 38, a 19% difference would be more meaningful in a population of 1,000 or 
greater.  It has been recognized that using VAS scores to measure pain can be subjective 
and may not be as valid a measurement when comparing a group of individuals as it 
would if it was used to identify changes in an individual.16   
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 An even more significant limitation to the Findlayson et al study,12 involved the 
randomization of the two groups.  The authors concluded after randomization that the 
patients in both groups had a significantly long duration of symptoms prior to entry into 
the study, but the BTX-A group had an average duration that was double the placebo 
group.  Patients in the BTX-A group averaged 6 years of symptoms, while the patients in 
the placebo group averaged 3 years.  With nTOS being described as a chronic and 
progressive disease,8 it would be difficult to understand how such a difference in duration 
of symptoms would not dramatically affect the results.  It could also be assumed that a 
longer duration of symptoms is accompanied by a later stage of disease progression, 
which could change the approach to treatment.  Presumably, a patient with a much 
greater duration of symptoms may not benefit from a single BTX-A injection, rather 
multiple injections or simply a more aggressive treatment.  In accordance with GRADE 
system,13 this randomized controlled trial could be given a quality score of low.  See 
Table I. 
 In the Christo et al4 and Jordan et al study,11 the results seemed to suggest that 
Botox could be successful short-term treatment for TOS or successful as a bridge therapy 
for patients considering surgery. These studies however, were prospective longitudinal 
studies and of quasi-experimental design that did not use a control group or account for 
the possibility of placebo effect.  The inclusion criteria for both studies could have been 
better defined.  For example, the pre-enrollment duration of symptoms for patients in 
both studies4,11 were broad and allowed for patients who may have had a significantly 
longer progression of the disease.  This potential longer duration of symptoms however, 
would only make the results more valid considering that a great majority of subjects had 
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relief of symptoms.  Also, in both studies the sample sizes used were small.  In terms of 
accuracy or injection placement, Christo et al3 performed their treatment under CT 
guidance, using a significantly smaller amount of botulinum toxin than in previous 
studies10,11 to reproduce a similar outcome.  This would suggest that other methods for 
confirmation of needle placement such as ultrasound and electromyography, which are 
using 3-5 times as much BTX-A,10,11 are lacking precision.  The results of these 
studies4,11 suggest a benefit for nTOS patients but need further refinement in order to be 
considered of higher quality according to the GRADE system.  Seeing that both studies 
are quasi-experimental studies, according to GRADE, they would be downgraded to a 
very low.  Both studies would have a more profound outcome if reproduced using a 
double-blind, randomized controlled trial with a larger sample size.  
CONCLUSION 
 Research to date on treatment of thoracic outlet syndrome with botulinum toxin, 
is lacking in quantity and quality.  The population sizes for all current studies have been 
very small and could significantly distort treatment effect.  There has also been 
imprecision in determining inclusion criteria, which allows for confounders such as 
severity and progression of disease.  However, two studies that have been performed 
show a significant improvement of symptoms.4,11   
 For most patients, nTOS can interfere with normal daily activities and can be 
debilitating to patients suffering from this diagnosis.  Also, the proper diagnosis and 
classification of TOS can be a controversial entity to clinicians due to its complex 
symptoms and lack of consistent clinical presentation.3,5 
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 Although two studies4,11 have demonstrated evidence of successful botulinum 
toxin treatment, more effort should be put into controlling the primary outcome measure 
by using a larger sample size, better randomization and blinding techniques and a more 
specific and well defined inclusion criteria.
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Table I. Characteristics of Reviewed Studies 
 
 
a Small sample size demonstrating non-significant confidence intervals 
b Failure of randomization with the treatment group having symptoms for an average of 6 years compared to 3 years in the control 
group 
c Quasi-experimental design lacking control group, randomization, and placebo. Also, broad inclusion criteria. 
d Small sample size 
 
 
Quality Assessment  
 Downgrade Criteria Quality 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
High; Moderate; 
Low; Very Low 
Finlayson et 
al12 
 
RCT 
Serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
Serious 
inconsistenciesb 
No bias likely Low 
Christo et al4  
Prospective 
Longitudinal Study 
Very serious 
limitationsc 
No serious 
indirectness 
Serious 
imprecisiond 
No inconsistencies No bias likely Very low  
Jordan et 
al11 
Prospective 
Very serious 
limitationsc 
No serious 
indirectness 
Serious 
imprecisiond 
No inconsistencies No bias likely Very low  
